A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy

Immunotherapy has greatly improved the survival time and quality of life of patients with renal cell carcinoma, but the benefits are limited to a small portion of patients. There are too few new biomarkers that can be used to identify molecular subtypes of renal clear cell carcinoma and predict surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jingwei, Cai, Yingxin, Ma, Yuxiang, Pan, Jinyou, Wang, Zuomin, Zhang, Jianpeng, Liu, Yangzhou, Zhao, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049491/
https://www.ncbi.nlm.nih.gov/pubmed/36982415
http://dx.doi.org/10.3390/ijms24065332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049491/
https://www.ncbi.nlm.nih.gov/pubmed/36982415
http://dx.doi.org/10.3390/ijms24065332

Ejemplares similares